CpG Island methylator phenotype predicts progression of malignant melanoma

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1801-1807

  Tanemura, Atsushi ^a   Terando, Alicia M ^a   Sim, Myung Shin ^a   Van Hoesel, Anneke Q ^a   De Maat, Michiel F G ^a   Morton, Donald L ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR GATA 4;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE; GENE LOCUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; METHYLATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; CHILD; CPG ISLANDS; DERMIS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; FIBROBLASTS; GENES, TUMOR SUPPRESSOR; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 63449140854     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1361     Document Type: Article

References (22)

1. Jema IA, Siege IR,Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
3. de Maat MF, Umetani N, Sunami E,Turner RR, Hoon DS. Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res 2007; 5:461 -71.
4. Kusano M,Toyota M, Suzuki H, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpGisland methylator phenotype and an association with Epstein-Barr virus. Cancer 2006;106:1467-79.
5. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumorsuppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-22.
6. Mori T, O'Day SJ, Umetani N, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23:9351 -8.
7. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigeneticin activation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006;
8. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-43.
9. Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007;33:653-9.
10. Nobeyama Y, Okochi-Takada E, Furuta J, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007;121:301 -7.
11. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-20.
12. Urakami S, Shiina H, Enokida H, et al. Epigenetic in-activation of Wnt inhibitory factor-1plays an important role in bladder cancer through aberrant canonical Wnt/h-catenin signaling pathway. Clin Cancer Res 2006;12:383-91.
13. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12:6989 -97.
14. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24: 7946-52.
15. Lin YC, You L, Xu Z, et al.Wnt inhibitory factor-1gene transfer inhibits melanoma cell growth. Hum Gene Ther 2007;18:379 -86.
16. Akiyama Y, Watkins N, Suzuki H, et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol 2003;23:8429-39.
17. Guo M, Akiyama Y, House MG, et al. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res 2004;10:7917-24.
18. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A1999; 96:8681 -6.
19. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9:2898-903.
20. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635 -48.
21. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18: 1427-31.
22. Umetani N, de Maat MF, Mori T, Takeuchi H, Hoon DS. Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase. Biochem Biophys Res Commun 2005;329:219-23.